Royal London Asset Management Reduces $59M in HCA Healthcare, Inc. ($HCA)
Royal London Asset Management cut its stake in HCA Healthcare by over 151,000 shares.
Key Points
- Royal London Asset Management reduced its holdings in HCA Healthcare by 151,456 shares, a 20.8% decrease, leaving 577,119 shares valued at $218.4 million.
- HCA shares traded at $378.51, with a market cap of $85.89 billion and a P/E ratio of 13.33.
- Insiders made recent trades, and analysts maintained various ratings with price targets ranging from $413 to $534.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Royal London Asset Management has reduced its stake in HCA Healthcare, Inc. (NYSE: HCA) by 151,456 shares, reflecting a 20.8% decrease in its holdings. This brings its total shares to 577,119, valued at approximately $218.4 million, according to its latest Form 13F filing with the SEC for the reporting period.
What Changed in Royal London Asset Management's HCA Healthcare Position
The asset management firm cut its position in HCA Healthcare from 728,575 shares to 577,119 shares, a reduction of 151,456 shares. This 20.8% decrease in shares reflects a strategic reallocation of its portfolio, leaving the remaining shares valued at $218.4 million.
Other Institutional Activity in HCA Healthcare
Other institutional investors have also made moves in HCA Healthcare. BlackRock, Inc. increased its holdings by 782,179 shares to a total of 13,363,266 shares, worth about $6.32 billion. Vanguard Capital Management LLC added 10,178,362 shares, bringing its total to the same amount, valued at $4.82 billion. Sanders Capital, LLC reduced its position by 1,507,023 shares, ending with 8,957,145 shares worth $4.24 billion. State Street Corp trimmed 27,093 shares, maintaining 7,539,550 shares valued at $3.57 billion. Meanwhile, FMR LLC and Wellington Management Group LLP increased their holdings by 567,650 and 483,726 shares, respectively.
HCA Healthcare, Inc. Stock Down 6.5%
Shares of HCA Healthcare (NYSE: HCA) traded near $378.51. The company has a market capitalization of approximately $85.89 billion and a P/E ratio of 13.33. Its stock has seen a 52-week low of $330.00 and a high of $556.52, with a 50-day moving average of $429.48 and a 200-day moving average of $460.93. The company's current ratio stands at 0.834, with a quick ratio of 0.643.
$HCA stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
HCA Healthcare reported revenue of $76.39 billion, with a revenue growth rate of 4.3%. The company's earnings per share (EPS) stood at $29.04, and it maintained a net margin of 8.89%. The return on equity was not specified, but the next earnings report is anticipated on April 24, 2026.
Dividend
HCA Healthcare offers an annual dividend rate of $3.12, yielding 0.81%. The dividend payout ratio is 10.13%, reflecting the company's commitment to returning value to shareholders.
Insider Buying and Selling at HCA Healthcare, Inc.
Recent insider activity at HCA Healthcare includes transactions by Executive Vice President and CFO Mike Marks, who sold and bought 3,336 shares on May 7, 2026. On April 28, 2026, insiders William Frist, Hugh Johnston, Michael Michelson, and Wayne Joseph Riley each purchased shares, with Frist and Johnston buying 809 shares each, Michelson buying 925 shares, and Riley purchasing 509 shares.
Analysts Set New Price Targets
On June 4, 2026, Bernstein maintained a hold rating on HCA Healthcare with a price target of $413. On April 27, 2026, several firms including TD Cowen, Barclays, RBC Capital, Stephens & Co., Keybanc, and Oppenheimer maintained buy ratings with targets ranging from $496 to $534. Wells Fargo maintained a hold rating with a $436 target. The consensus recommendation for HCA is a buy, with an average target price of $503.57 based on 21 analyst opinions.
About HCA Healthcare
HCA Healthcare, Inc. is a major healthcare service provider in the United States, operating from its headquarters in Nashville, Tennessee. The company, led by CEO Samuel N. Hazen, employs around 230,000 people and runs a network of hospitals, outpatient centers, and other healthcare facilities. Founded in 1968, HCA offers a wide range of medical services, including emergency care, surgery, and rehabilitation.
Bottom Line
Investors are closely watching Royal London Asset Management's reduction in its HCA Healthcare stake, reflecting strategic portfolio adjustments. HCA's stock performance and financial health remain in focus, with its significant market cap and analyst interest. As always, 13F filings provide a historical view and may not reflect current positions.
Get HCA Healthcare, Inc. alerts
New 13F filings, insider trades, and analyst moves on $HCA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.